https://www.selleckchem.com/products/AZ-960.html
Our review will enable more comprehensive therapeutic approaches to prevent the development and/or progression of OIS.Alzheimer's disease is a fatal neurodegenerative malady which up to very recently did not have approved therapy modifying its course. After controversial approval of aducanumab (monoclonal antibody clearing β-amyloid plaques) by FDA for use in very early stages of disease, possibly new avenue opened for the treatment of patients. In line with this approach is search for compounds blocking aggregation into amyloid oligomer
Like
Comment
Share
